Second-Quarter Revenue at Celgene Surpasses Wall Street Targets
July 30 2019 - 8:43AM
Dow Jones News
By Micah Maidenberg
Celgene Corp. (CELG) beat revenue estimates for the second
quarter as it prepares to merge with Bristol-Myers Squibb Co.
The company said Tuesday sales rose 15% from the year earlier to
$4.4 billion. Analysts expected $4.24 billion, according to
FactSet.
Celgene reported a profit of $1.57 billion, or $2.16 a share, up
from $1.05 billion, or $1.43 a share, a year earlier. The company's
adjusted earnings of $2.86 a share after adjustments surpassed the
$2.63 a share analysts were looking for.
Second-quarter sales of the blood cancer drug Revlimid, a major
product for Celgene, rose 11% from the year earlier.
Bristol-Myers and Celgene anticipate the Bristol-Myers will
complete its acquisition of Celgene by the end of this year or in
early 2020.
Celgene also said it now expects revenue between $17.2 billion
and $17.4 billion for 2019. That's up from a previous forecast that
predicted no more than $17.2 billion in revenue. It said adjusted
earnings for the year will range from $10.60 to $10.85 a share, up
from $10.60 to $10.80 a share.
Celgene reaffirmed its previous revenue and adjusted-profit
outlook for 2020. It also said that due to the pending transaction
with Bristol-Myers it didn't anticipate updating that forecast.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
July 30, 2019 08:28 ET (12:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024